Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin M Balko

Showing results (21-30 of 174) with videos related to

Pageof 18
Sort By:
Cancer Journal (Sudbury, Mass.)|January 21, 2021
Triple-Negative Breast Cancer: Breast Tumors With an Identity CrisisSara E Nunnery, Ingrid A Mayer, Justin M Balko
Oncoimmunology|May 12, 2020
Progesterone receptor promotes degradation of STAT2 to inhibit the interferon response in breast cancerKatherine R Walter, Justin M Balko, Christy R Hagan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2023
Corticosteroids and Cancer ImmunotherapyRachel S Goodman, Douglas B Johnson, Justin M Balko
Seminars in Cancer Biology|September 18, 2017
Emerging biomarkers for cancer immunotherapy in melanomaMargaret L Axelrod, Douglas B Johnson, Justin M Balko
Immunological Reviews|July 20, 2023
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunitiesRachel S Goodman, Seungyeon Jung, Justin M Balko, et al.
Seminars in Cutaneous Medicine and Surgery|July 25, 2018
Biomarkers for immune therapy in melanomaDouglas B Johnson, Jeewon Chon, Mark R Johnson, et al.
Biochemical and Biophysical Research Communications|October 20, 2009
Deregulation of DUSP activity in EGFR-mutant lung cancer cell lines contributes to sustained ERK1/2 signalingJoel S Britson, Frederick Barton, Justin M Balko, et al.
Cancer Immunology Research|July 5, 2024
Unveiling Cellular Identities and Gene Expression Pathways in Overlapping Myocarditis and MyositisReilly G Fankhauser, Douglas B Johnson, Javid J Moslehi, et al.
Cancer Drug Resistance (Alhambra, Calif.)|October 16, 2020
MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expressionDerek A Franklin, Jamaal L James, Margaret L Axelrod, et al.
Cancer Biology & Therapy|March 24, 2009
MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLCJustin M Balko, Brett R Jones, Virginia L Coakley, et al.
Pageof 18

Showing results (21-30 of 174) with videos related to

Sort By:
Pageof 18
Cancer Journal (Sudbury, Mass.)|January 21, 2021
Triple-Negative Breast Cancer: Breast Tumors With an Identity CrisisSara E Nunnery, Ingrid A Mayer, Justin M Balko
Oncoimmunology|May 12, 2020
Progesterone receptor promotes degradation of STAT2 to inhibit the interferon response in breast cancerKatherine R Walter, Justin M Balko, Christy R Hagan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2023
Corticosteroids and Cancer ImmunotherapyRachel S Goodman, Douglas B Johnson, Justin M Balko
Seminars in Cancer Biology|September 18, 2017
Emerging biomarkers for cancer immunotherapy in melanomaMargaret L Axelrod, Douglas B Johnson, Justin M Balko
Immunological Reviews|July 20, 2023
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunitiesRachel S Goodman, Seungyeon Jung, Justin M Balko, et al.
Seminars in Cutaneous Medicine and Surgery|July 25, 2018
Biomarkers for immune therapy in melanomaDouglas B Johnson, Jeewon Chon, Mark R Johnson, et al.
Biochemical and Biophysical Research Communications|October 20, 2009
Deregulation of DUSP activity in EGFR-mutant lung cancer cell lines contributes to sustained ERK1/2 signalingJoel S Britson, Frederick Barton, Justin M Balko, et al.
Cancer Immunology Research|July 5, 2024
Unveiling Cellular Identities and Gene Expression Pathways in Overlapping Myocarditis and MyositisReilly G Fankhauser, Douglas B Johnson, Javid J Moslehi, et al.
Cancer Drug Resistance (Alhambra, Calif.)|October 16, 2020
MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expressionDerek A Franklin, Jamaal L James, Margaret L Axelrod, et al.
Cancer Biology & Therapy|March 24, 2009
MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLCJustin M Balko, Brett R Jones, Virginia L Coakley, et al.
Pageof 18